MA44503B1 - PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS - Google Patents

PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS

Info

Publication number
MA44503B1
MA44503B1 MA44503A MA44503A MA44503B1 MA 44503 B1 MA44503 B1 MA 44503B1 MA 44503 A MA44503 A MA 44503A MA 44503 A MA44503 A MA 44503A MA 44503 B1 MA44503 B1 MA 44503B1
Authority
MA
Morocco
Prior art keywords
pyrrolotriazine compounds
inhibitors
tam inhibitors
compounds
tam
Prior art date
Application number
MA44503A
Other languages
French (fr)
Other versions
MA44503A (en
Inventor
xiaozhao Wang
Chunhong He
Yun-Long Li
Joseph Barbosa
David M Burns
Hao Feng
Joseph Glenn
Taisheng Huang
Song Mei
Jincong Zhuo
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Priority claimed from PCT/US2017/024270 external-priority patent/WO2017172596A1/en
Publication of MA44503A publication Critical patent/MA44503A/en
Publication of MA44503B1 publication Critical patent/MA44503B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette demande concerne des composés de formule i, ou des sels pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de tam kinases utiles pour le traitement de troubles tels que le cancer.This application relates to compounds of formula i, or pharmaceutically acceptable salts thereof, which are inhibitors of tam kinases useful for the treatment of disorders such as cancer.

MA44503A 2016-03-28 2017-03-27 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MA44503B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314066P 2016-03-28 2016-03-28
PCT/US2017/024270 WO2017172596A1 (en) 2016-03-28 2017-03-27 Pyrrolotriazine compounds as tam inhibitors

Publications (2)

Publication Number Publication Date
MA44503A MA44503A (en) 2019-02-06
MA44503B1 true MA44503B1 (en) 2023-11-30

Family

ID=63036861

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44503A MA44503B1 (en) 2016-03-28 2017-03-27 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS

Country Status (2)

Country Link
AR (1) AR107984A1 (en)
MA (1) MA44503B1 (en)

Also Published As

Publication number Publication date
MA44503A (en) 2019-02-06
AR107984A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
MA43169B1 (en) Heterocyclic compounds as pi3k-gamma inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MA52486B1 (en) Pyridazinones used as parp7 inhibitors
MA47079A (en) AMINO-TRIAZOLOPYIDINE COMPOUNDS AND THEIR USE TO TREAT CANCER
MA40123A1 (en) Pyrimidines used as factor xia inhibitors
MA44721B1 (en) Macrocyclic mcl1 inhibitors for cancer treatment
MA39898B1 (en) 4-amino-imidazoquinoline compounds
MA40111A1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MA40225A (en) SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
MA45153B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MA38483A1 (en) Inhibitors of ido
MA40955B1 (en) 2-amino-6- (difluoromethyl) -5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
TN2015000347A1 (en) AZABENZIMIDAZOLES AS INHIBITORS OF PDE4 ISOENZYMES FOR THE TREATMENT OF CNS DISORDERS AND OTHER DISORDERS
MA54386B1 (en) TREX1 MODULATORS
MA54133A (en) AMINOPYRAZINE DIOL COMPOUNDS USED AS PI3K-Y INHIBITORS
MA43409B1 (en) Polycyclic compounds for use as bruton tyrosine kinase inhibitors
MA46229B1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MA39171A1 (en) Hydroxy formamide derivatives and their use
MA50398B1 (en) Condensed imidazole derivatives, substituted by tertiary hydroxy groups, used as inhibitors of pi3k-gamma
MA37765A1 (en) Substituted pyrazole compounds used as lpar antagonists
EA201692260A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
MA43913B1 (en) Positive allosteric modulators of the m1 muscarinic receptor
MA39337A1 (en) Modulators of pyrazines of gpr6
MA46965B1 (en) Gamma ror (rory) modulators
MA39229A1 (en) Pyrrolidines, terrahydrofurans and substituted cyclopentanes useful as orexin receptor antagonists